We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AREXVY GlaxoSmithKline Australia Pty Ltd
Product name
AREXVY
Accepted date
Oct-2025
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein
Proposed indication
AREXVY is is a vaccine proposed for active immunisation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 18 years of age and older.
The use of this vaccine should be in accordance with official recommendations.
The use of this vaccine should be in accordance with official recommendations.
Application type
C (new indication)
Publication date
Oct-2025